Jul 17, 2025
Oncotelic Therapeutics Highlights Peer Reviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer Patients
Jun 25, 2025
Oncotelic Therapeutics Announces Publication of Landmark Study on TGFB2 Gene Methylation as a Positive Prognostic Marker in Pancreatic Cancer
Apr 22, 2025
Oncotelic CEO Vuong Trieu to Present Innovative "Deciparticles" Platform at IDDST-Europe 2025 Conference in Stockholm
Apr 16, 2025
Oncotelic Therapeutics Reports FY 2024 Highlights and FY 2024 Earnings Compared to FY 2023
Mar 31, 2025
Oncotelic Therapeutics Publishes New Research Demonstrating Positive Prognostic Impact of Methylated TGFB2 and MGMT in Adult Glioblastoma Patients, Introduces Interactive PDAOAI
Mar 25, 2025
Oncotelic Therapeutics Announces Successful Completion of Phase 1 Trial of OT-101 and IL-2, Highlights Findings at SWCR 2025 Conference
Feb 25, 2025
Oncotelic Accesses Rapid IND Development Platform through Partnership with Medicilon
Feb 13, 2025
Oncotelic CEO Vuong Trieu to Present Groundbreaking Research on Transforming Growth Factor Beta 2 (TGFB2) at SWCR 2025 Conference
Dec 31, 2024
Oncotelic Therapeutics Implements PDAOAI Platform
Nov 06, 2024
ONCOTELIC CLINICAL PRESENTATIONS AT SITC 2024
1
2
3
4
5
6
<<
<
>
>>
Copyright © 2021 Oncotelic Inc., a TGF ImmunoOncology Company. All rights reserved.
Privacy
